Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy

Edén, Arvid; Price, Richard W.; Spudich, Serena; Fuchs, Dietmar; Hagberg, Lars; Gisslén, Magnus
December 2007
Journal of Infectious Diseases;12/15/2007, Vol. 196 Issue 12, p1779
Academic Journal
Highly active antiretroviral therapy (HAART) effectively reduces human immunodeficiency virus (HIV) RNA in cerebrospinal fluid (CSF), as well as in plasma. The effect on intrathecal immunoactivation is less well studied. We had earlier found that a substantial number of patients still have evidence of intrathecal immunoactivation after up to 2 years of treatment. We identified 15 patients treated with HAART for ⩾4 years who had plasma HIV-RNA levels of <50 copies/mL for ⩾3.5 years. CSF samples were available from 10 patients before treatment. We measured white-blood-cell count, HIVRNA level, neopterin level, and IgG index. During treatment, all patients had HIV-RNA levels of <50 copies/mL in plasma and CSF. In CSF, both neopterin level and IgG index decreased significantly. After 4 years, 9 (60%) of the 15 patients still had neopterin levels in CSF that were above the upper normal reference value (5.8 nmol/L). During HAART, 9 (60%) of the 15 patients had an abnormal IgG index (>0.63). HAART significantly decreases intrathecal immunoactivation, but, despite effective treatment for >4 years, with HIV-RNA levels <50 copies/mL for⩾3.5 years, a substantial proportion of patients continue to show signs of macrophage/microglia activation and intrathecal immunoglobulin production in the CNS.


Related Articles

  • Antiretroviral Medication Errors among Hospitalized Patients with HIV Infection. Rastegar, Darius A.; Knight, Amy M.; Monolakis, Jim S. // Clinical Infectious Diseases;10/1/2006, Vol. 43 Issue 7, p933 

    Background. Highly active antiretroviral therapy (HAART) has improved survival for persons living with human immunodeficiency virus (HIV) infection. However, effective therapy requires high levels of adherence over extended periods of time. Previous studies suggest that patients receiving...

  • Oral Lesions as Clinical Markers of Highly Active Antiretroviral Therapy Failure: A Nested Case-Control Study in Mexico City. Ramírez-Amador, Velia; Ponce-de-León, Sergio; Anaya-Saavedra, Gabriela; Ramírez, Brenda Crabtree; Sierra-Madero, Juan // Clinical Infectious Diseases;10/1/2007, Vol. 45 Issue 7, p925 

    Background. Clinical markers that may predict virological failure during highly active antiretroviral therapy (HAART) have not been evaluated adequately. The aim of the present study was to evaluate the usefulness of human immunodeficiency virus (HIV)-related oral lesions as clinical predictors...

  • Are All Subtypes Created Equal? The Effectiveness of Antiretroviral Therapy against Non-Subtype B HIV-1. Pond, Sergei L. Kosakovsky; Smith, Davey M. // Clinical Infectious Diseases;5/1/2009, Vol. 48 Issue 9, p1306 

    The article reports on the study regarding the effectiveness of modern combination of antiretroviral therapy against non-subtype B HIV-1 in the U.S. It states that the study examined the rates of viral suppression with antiretroviral therapy during infection with subtypes A, C, and D and with...

  • Rate and Predictors of Self-Chosen Drug Discontinuations in Highly Active Antiretroviral Therapy-Treated HIV-Positive Individuals. Murri, Rita; Guaraldi, Giovanni; Lupoli, Piergiorgio; Crisafulli, Raffaella; Marcotullio, Simone; von Schloesser, Filippo; Wu, Albert W. // AIDS Patient Care & STDs;Jan2009, Vol. 23 Issue 1, p35 

    Despite the clinical benefits of highly active antiretroviral therapy (HAART), sustained treatment remains a great challenge for HIV-infected people. The rate, consequences, and correlates of self-elected treatment interruptions (TI) are not known. The objectives of the study were to assess the...

  • Highly active antiretroviral therapy and hospital readmission: comparison of a matched cohort. Nosyk, Bohdan; Huiying Sun; Xin Li; Palepu, Anita; Anis, Aslam H // BMC Infectious Diseases;2006, Vol. 6 Issue 1, p146 

    Background: Despite the known efficacy of highly active antiretroviral therapy (HAART), a large proportion of potentially-eligible HIV-infected patients do not access, and may stand to benefit from this treatment. In order to quantify these benefits in terms of reductions in hospitalizations and...

  • HAART. Vohr, Hans-Werner // Encyclopedic Reference of Immunotoxicology;2005, p269 

    A definition of the term "highly active antiretroviral therapy" is presented. It refers to a combination of drugs used to control replication of the HIV virus in infected patients.

  • Predictors of early death in a cohort of Ethiopian patients treated with HAART. Jerene, Degu; Endale, Aschalew; Hailu, Yewubnesh; Lindtjørn, Bernt // BMC Infectious Diseases;2006, Vol. 6 Issue 1, p136 

    Background: HAART has improved the survival of HIV infected patients. However, compared to patients in high-income countries, patients in resource-poor countries have higher mortality rates. Our objective was to identify independent risk factors for death in Ethiopian patients treated with...

  • Dried Blood Spots Perform Well in Viral Load Monitoring of Patients Who Receive Antiretroviral Treatment in Rural Tanzania. Johannessen, Asgeir; Garrido, Carolina; Zahonero, Natalia; Sandvik, Leiv; Naman, Ezra; Kivuyo, Sokoine L.; Kasubi, Mabula J.; Gundersen, Svein G.; Bruun, Johan N.; de Mendoza, Carmen // Clinical Infectious Diseases;9/15/2009, Vol. 49 Issue 6, p976 

    Background. Monitoring of antiretroviral treatment (ART) with human immunodeficiency virus (HIV) viral loads, as recommended in industrialized countries, is rarely available in resource-limited settings because of the high costs and stringent requirements for storage and transport of plasma....

  • Increased risk of deep neck infection among HIV-infected patients in the era of highly active antiretroviral therapy--a population-based follow-up study. Ching-Feng Liu; Shih-Feng Weng; Yung-Song Lin; Chih-Sheng Lin; Ching-Feng Lien; Jhi-Joung Wang // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: Deep neck infections (DNIs) in HIV-infected patients often produce severe complications, even death. Data on the incidence rates and risks of DNI among HIV-infected patients are scarce, particularly with the widespread use of highly active antiretroviral therapy (HAART). We evaluated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics